AR and pachyonychia congenita: Despite the small patient’s cohort analyzed in this study, the resulting findings would help to stratify PC patients who benefit from abiraterone or enzalutamide therapy, since AR amplification [81] and AR-V7 mutant [82] represent valuable biomarkers for treatment guidance in castration resistant PC (CRPC).